-
公开(公告)号:US08409838B2
公开(公告)日:2013-04-02
申请号:US12791637
申请日:2010-06-01
申请人: Gang Chen , Darya Burakov , James P. Fandl
发明人: Gang Chen , Darya Burakov , James P. Fandl
CPC分类号: C12P21/005 , C07K16/00 , C07K16/2863 , C07K16/2866 , C07K2317/14 , C07K2317/41 , C12N9/0006 , C12N15/00 , C12Y101/01271 , Y02P20/52
摘要: An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.
-
12.
公开(公告)号:US20100316636A1
公开(公告)日:2010-12-16
申请号:US12780006
申请日:2010-05-14
申请人: Allen Radin , Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Eric Smith , Kevin J. Pobursky , Nicholas J. Papadopoulos , James P. Fandl , Gang Chen , Margaret Karow
发明人: Allen Radin , Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Eric Smith , Kevin J. Pobursky , Nicholas J. Papadopoulos , James P. Fandl , Gang Chen , Margaret Karow
IPC分类号: A61K39/395 , A61P19/02 , A61P29/00
CPC分类号: A61K39/3955 , A61K31/4706 , A61K31/519 , A61K31/655 , A61K38/191 , A61K39/39541 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/248 , C07K16/2866 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y10S514/885 , A61K2300/00
摘要: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.
摘要翻译: 本发明提供使用特异性结合人白细胞介素-6受体(hIL-6R)的完全人抗体或其抗原结合片段预防或治疗类风湿性关节炎的方法。 本发明的方法可以包括施用第二治疗剂,例如非甾体抗炎药(NSAID),糖皮质激素,疾病缓解性抗风湿药(DMARD)中的一种或多种,或 TNF-α拮抗剂,T细胞阻断剂,抗CD20抗体,IL-1,JAK或IL-17拮抗剂或其任何组合。
-
公开(公告)号:US20100316627A1
公开(公告)日:2010-12-16
申请号:US12501657
申请日:2009-07-13
申请人: Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Eric Smith , Kevin J. Pobursky , Nicholas J. Papadopoulos , James P. Fandl , Gang Chen , Margaret Karow
发明人: Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Eric Smith , Kevin J. Pobursky , Nicholas J. Papadopoulos , James P. Fandl , Gang Chen , Margaret Karow
CPC分类号: C07K16/2866 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.
摘要翻译: 以约500pM以下的KD结合人IL-6受体(hIL-6R)的人抗体或抗原结合片段,并以200pM以下的IC 50阻断IL-6活性。 在优选的实施方案中,抗体抗体或抗原结合片段以相对于其结合猴IL-6R至少高2倍的亲和力结合hIL-6R。
-
公开(公告)号:US20100233803A1
公开(公告)日:2010-09-16
申请号:US12466606
申请日:2009-05-15
CPC分类号: C07K14/71 , C07H21/04 , C07K16/2863 , C07K2317/31 , C07K2317/52 , C07K2317/622 , C07K2317/75 , C07K2319/30 , C12P21/02
摘要: A fusion polypeptide comprising (A)x-M-(A′)y, wherein A and A′ are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A′ may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different ScFv fragments, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.
摘要翻译: 包含(A)x-M-(A')y的融合多肽,其中A和A'是能够结合靶受体的多肽。 本发明的融合多肽形成激活靶受体的多聚体蛋白。 A和A'可以各自为衍生自靶受体(例如相同或不同ScFv片段)的特异性抗体的抗体或片段,和/或能够结合靶蛋白质的配体或配体片段或衍生物,M为 多聚化组分,X和Y独立地为1-10之间的数。
-
公开(公告)号:US08389239B2
公开(公告)日:2013-03-05
申请号:US12793898
申请日:2010-06-04
申请人: Gang Chen , Robert Babb , James P. Fandl
发明人: Gang Chen , Robert Babb , James P. Fandl
IPC分类号: C12P21/02
CPC分类号: C12N15/85 , C07K16/00 , C07K2319/30 , C12N15/86 , C12N2740/10043 , C12N2800/30 , C12N2840/203 , C12P21/02
摘要: Expression-enhancing nucleotide sequences for expression in eukaryotic systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Enhanced expression and stability regions (EESYRs) are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.
-
16.
公开(公告)号:US20120258098A1
公开(公告)日:2012-10-11
申请号:US13462938
申请日:2012-05-03
申请人: Allen Radin , Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Eric Smith , Kevin J. Pobursky , Nicholas J. Papadopoulos , James P. Fandl , Gang Chen , Margaret Karow
发明人: Allen Radin , Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Eric Smith , Kevin J. Pobursky , Nicholas J. Papadopoulos , James P. Fandl , Gang Chen , Margaret Karow
IPC分类号: A61K39/395 , A61P29/00
CPC分类号: A61K39/3955 , A61K31/4706 , A61K31/519 , A61K31/655 , A61K38/191 , A61K39/39541 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/248 , C07K16/2866 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y10S514/885 , A61K2300/00
摘要: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.
摘要翻译: 本发明提供使用特异性结合人白细胞介素-6受体(hIL-6R)的完全人抗体或其抗原结合片段预防或治疗类风湿性关节炎的方法。 本发明的方法可以包括施用第二治疗剂,例如非甾体抗炎药(NSAID),糖皮质激素,疾病缓解性抗风湿药(DMARD)中的一种或多种,或 TNF-α拮抗剂,T细胞阻断剂,抗CD20抗体,IL-1,JAK或IL-17拮抗剂或其任何组合。
-
公开(公告)号:US20090162901A1
公开(公告)日:2009-06-25
申请号:US12323161
申请日:2008-11-25
申请人: Gang Chen , Changlin Dou , James P. Fandl
发明人: Gang Chen , Changlin Dou , James P. Fandl
IPC分类号: C12P21/00
CPC分类号: C12N15/635 , A01K2217/05 , C07K16/00 , C07K2317/14 , C07K2317/21 , C07K2319/00 , C12N15/63 , C12N15/85 , C12N2830/00 , C12N2830/15 , C12N2830/42 , C12N2840/20 , C12P21/00
摘要: Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.
摘要翻译: 提供了在真核细胞中可诱导表达基因的组合物和方法。 通过由转录阻断结构域和配体结合结构域组成的调节融合蛋白来控制感兴趣的蛋白质的目标核苷酸序列的表达。 当存在配体结合结构域的同源配体时,感兴趣的核苷酸序列的转录被阻断。 去除同源配体后,转录目的核苷酸序列。 该方法可用于在真核细胞中大规模生物反应器生产期望的蛋白质。
-
公开(公告)号:US07534604B2
公开(公告)日:2009-05-19
申请号:US11035599
申请日:2005-01-14
CPC分类号: C07K16/2863 , C07H21/04 , C07K2317/31 , C07K2317/52 , C07K2317/622 , C07K2317/75 , C07K2319/30
摘要: A fusion polypeptide comprising (A)x-M-(A′)y, wherein A and A′ are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A′ may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different ScFv fragments, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.
摘要翻译: 包含(A)x-M-(A')y的融合多肽,其中A和A'是能够结合靶受体的多肽。 本发明的融合多肽形成激活靶受体的多聚体蛋白。 A和A'可以各自为衍生自靶受体(例如相同或不同ScFv片段)的特异性抗体的抗体或片段,和/或能够结合靶蛋白质的配体或配体片段或衍生物,M为 多聚化组分,X和Y独立地为1-10之间的数。
-
公开(公告)号:US08673589B2
公开(公告)日:2014-03-18
申请号:US12323161
申请日:2008-11-25
申请人: Gang Chen , Changlin Dou , James P. Fandl
发明人: Gang Chen , Changlin Dou , James P. Fandl
CPC分类号: C12N15/635 , A01K2217/05 , C07K16/00 , C07K2317/14 , C07K2317/21 , C07K2319/00 , C12N15/63 , C12N15/85 , C12N2830/00 , C12N2830/15 , C12N2830/42 , C12N2840/20 , C12P21/00
摘要: Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.
摘要翻译: 提供了在真核细胞中可诱导表达基因的组合物和方法。 通过由转录阻断结构域和配体结合结构域组成的调节融合蛋白来控制感兴趣的蛋白质的目标核苷酸序列的表达。 当存在配体结合结构域的同源配体时,感兴趣的核苷酸序列的转录被阻断。 去除同源配体后,转录目的核苷酸序列。 该方法可用于在真核细胞中大规模生物反应器生产期望的蛋白质。
-
公开(公告)号:US08298532B2
公开(公告)日:2012-10-30
申请号:US12466606
申请日:2009-05-15
IPC分类号: C07K16/28 , A61K39/395
CPC分类号: C07K14/71 , C07H21/04 , C07K16/2863 , C07K2317/31 , C07K2317/52 , C07K2317/622 , C07K2317/75 , C07K2319/30 , C12P21/02
摘要: A fusion polypeptide comprising (A)x-M-(A′)y, wherein A and A′ are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A′ may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different scFv fragments, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.
摘要翻译: 包含(A)x-M-(A')y的融合多肽,其中A和A'是能够结合靶受体的多肽。 本发明的融合多肽形成激活靶受体的多聚体蛋白。 A和A'可以各自为来自对靶受体特异的抗体的抗体或片段,例如相同或不同的scFv片段,和/或能够结合靶蛋白的配体或配体片段或衍生物,M是 多聚化组分,X和Y独立地为1-10之间的数。
-
-
-
-
-
-
-
-
-